IRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, announces a new investment in ExCellThera Inc., a clinical-stage cell and molecular medicine company which it co-founded in 2015.
Read More
IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase 1 clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.
Read More
McGill University and CQDM announced today that a collaborative project between McGill and nplex biosciences to further develop a highly-scalable protein detection method, termed the “nELISA”, has been selected for funding by CQDM.
Read More
The pandemic has highlighted the importance of supporting scientific research in order to allow investigators to find real solutions to deal with public health issues such as COVID-19 or cancer.
Read More
IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, provides further details today on the Company’s rapid progress in developing its candidate vaccine to prevent COVID-19 infection in response to the global health threat posed by the novel coronavirus.
Read More
Today BML Technology is proud to announce the launch of the COVID-19 Digital Health Task Force, in collaboration with elite partners and collaborators from the core of the Montreal health tech ecosystem, including the CNRC, McGill University, le CHUM, Fasken Martineau DuMoulin, Montreal InVivo, and Avisio Qualité, as well as institutions with international reach, like Montréal International and Medteq+.
Read More
The CQDM is launching its new SynergiQc program, designed to stimulate industrial research in the biopharmaceutical field within academic settings and to create economic benefits for Quebec.
Read More
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, today announced it has entered into an exclusive, worldwide research collaboration with Bristol Myers Squibb (BMS) (NYSE:BMY).
Read More
IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive preclinical results demonstrating robust immunogenic and antibody responses from the majority of peptide epitopes.
Read More
Alethia Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial to mesenchymal transition (EMT).
Read More
Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.
Read More
DIEX Recherche is proud to announce the opening of its fourth research center in Quebec. CEO Suzie Talbot made the announcement at DIEX Recherche in Sherbrooke. She insists that it is important to have good news to share these days. The opening of a new center will provide the local population of this beautiful region with innovative clinical trials.
Read More
New information on COVID-19 emerges every day. Researchers and scientists in Canada and around the world are working hard to better understand the virus, and its impacts on people and communities. By keeping pace with this information, we can better protect the health of Canadians and set our country on the path to recovery.
Read More
Immune Biosolutions, Diex Research, Keyrus Life Science and the Faculty of Medicine and Health Sciences of the Université de Sherbrooke (FMSS) are joining forces to discover and develop innovative solutions against the SARS-CoV-2 virus.
Read More
Glycovax Pharma, a biopharmaceutical company based in Montréal, is actively working on the development of a new vaccine approach to counter COVID-19. The prototype glycoconjugate vaccine is currently in the preclinical phase.
Read More
New features, including fever, symptom and medication tracking, are now available for free to first-time users to support high-risk populations navigating COVID-19.
Read More
Roche Canada is pleased to announce the launch of the Roche Data Science Coalition, a group of like-minded public and private organizations committed to working with the global community to develop solutions to the challenges of the COVID-19 pandemic. The collaborators in the Coalition include: Alberta Machine Intelligence Institute (Amii), doc.ai, NVIDIA, Self Care Catalysts, ThinkData Works Inc and Vector Institute.
Read More
Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that spun off from McGill University in 2012, today announces that it is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.
Read More
Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development has joined the battle to fight the novel COVID-19 virus. The Company will mobilize its expertise in regulatory affairs and quality assurance to support Canadian businesses seeking Health Canada approval for specific products used to mitigate the ongoing COVID-19 pandemic.
Read More